

## Controversies in metastatic prostate cancer

Thematic Session 17

**Monday, 27 March**  
**10:30 - 12:00**

**Location:** Room Stockholm, North Hall (Level 1)

**Chair:** M-O. Grimm, Jena (DE)

### **Aims and objectives of this session**

This session will summarise most recent developments in castration sensitive and castration resistant metastatic prostate cancer. In particular, surgical resection of oligometastatic disease, new biomarkers and targets are to be discussed as part of individualised patient care. Furthermore, the upcoming role of immunotherapy in prostate cancer will be presented.

10:30 - 10:50

**Debate Is there a role for local treatment of oligometastatic disease?**

10:30 - 10:40

**Yes**

M. Spahn, Berne (CH)

10:40 - 10:50

**No**

B. Tombal, Brussels (BE)

10:50 - 11:05

**State-of-the-art lecture EAU Guidelines on mCRPC - An update**

P. Cornford, Liverpool (GB)

11:05 - 11:07

**Introduction Society for Urologic Oncology (SUO)**

C.R. Chapple, Sheffield (GB)

11:07 - 11:20

**Society for Urologic Oncology (SUO) lecture Current and future biomarkers in castration resistant prostate cancer**

C.P. Evans, Sacramento (US)

11:20 - 11:35

**State-of-the-art lecture Next generation targets for individualised treatment**

J. De Bono, Sutton (GB)

11:35 - 11:50

**State-of-the-art lecture Update on immunotherapy - Revival of the fittest?**

K. Fizazi, Villejuif (FR)

11:50 - 12:00

**Associated abstract presentation**

748

**Targeting androgen receptor variants by niclosamide overcomes resistance to abiraterone and enzalutamide**

**By:** Liu C., Lou W., Pan C-X., Evans C., [Gao A.](#)

**Institutes:**University of California Davis, Dept. of Urology, Sacramento, United States of America

**State-of-the-art lecture**